Tumor Size Differences Between Preoperative Endoscopic Ultrasound and Postoperative Pathology for Neoadjuvant-Treated Pancreatic Ductal Adenocarcinoma Predict Patient Outcome

< Back to Publications
December 2, 2020
Clin. Gastroenterol. Hepatol. (2020/2021). [In press]
R. Das, K. McGrath, N. Seiser, K. Smith, S. Uttam, R. E. Brand, K. E. Fasanella, A. Khalid, J. S. Chennat, S. Sarkaria, H. Singh, A. Slivka, H. J. Zeh, A. H. Zureikat, M. E. Hogg, K. K. Lee, A. Paniccia, M. C. Ongchin, J. F. Pingpank, B. A. Boone, A. K. Dasyam, N. Bahary, V. C. Gorantla, J. C. Rhee, R. Thomas, S. Ellsworth, M. S. Landau, N. Paul Ohori, P. Henn, S. Shyu, B. K. Theisen, A. D. Singhi

Background & aims: The assessment of therapeutic response after neoadjuvant treatment and pancreatectomy for pancreatic ductal adenocarcinoma (PDAC) has been an ongoing challenge. Several limitations have been encountered when employing current grading systems for residual tumor. Considering endoscopic ultrasound (EUS) represents a sensitive imaging technique for PDAC, differences in tumor size between preoperative EUS and postoperative pathology after neoadjuvant therapy were hypothesized to represent an improved marker of treatment response. Methods: For 340 treatment-naive and 365 neoadjuvant-treated PDACs, EUS and pathologic findings were analyzed and correlated with patient overall survival (OS). A separate group of 200 neoadjuvant-treated PDACs served as a validation cohort for further analysis. Results: Among treatment-naive PDACs, there was a moderate concordance between EUS imaging and postoperative pathology for tumor size (r = 0.726, P < .001) and AJCC 8th edition T-stage (r = 0.586, P < .001). In the setting of neoadjuvant therapy, a decrease in T-stage correlated with improved 3-year OS rates (50% vs 31%, P < .001). Through recursive partitioning, a cutoff of ≥ 47% tumor size reduction was also found to be associated with improved OS (67% vs 32%, P < .001). Improved OS using ≥ 47% threshold was validated using a separate cohort of neoadjuvant-treated PDACs (72% vs 36%, P < .001). By multivariate analysis, a reduction in tumor size by ≥ 47% was an independent prognostic factor for improved OS (P = .007). Conclusions: The difference in tumor size between preoperative EUS imaging and postoperative pathology among neoadjuvant-treated PDAC patients is an important prognostic indicator and may guide subsequent chemotherapeutic management.